FIGURE 4.
(a) ALK secondary mutation following disease progression on alectinib. (b) Progression‐free survival during the treatment of subsequent ALK‐TKI between patients with or without secondary ALK mutation
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.